Biomega appoints former Benchmark Genetics CEO as new managing director

Norwegian biorefining specialist Biomega Group has announced the appointment of Dr Geir Olav Melingen, former CEO of Benchmark Genetics, as its new managing director.

Biomega, a biorefining specialist which develops sustainable proteins, oils and peptides from salmon by-products, said Melingen’s experience in aquaculture and biotechnology will support its plans for innovation and growth in the global ingredients market.

“We are very excited to welcome Dr. Melingen to lead the next growth phase of Biomega Group,” said Sten Estrup, Chairman of Biomega Group, via a press release.

“His extensive international experience and proven track record of business transformation make him the ideal fit to Biomega. Dr. Melingen’s deep knowledge of the aquaculture industry, his commercial acumen and people-centric leadership philosophy align perfectly with Biomega’s values and vision. We are confident that under his guidance, Biomega will continue to strengthen its position as a leader in sustainable ingredients, Estrup added.

Melingen, who holds a doctoral degree in fish health, was formerly CEO and Head of Salmon, Health & Genetics at Benchmark Genetics, where he managed operations across Norway, Iceland and Chile. His earlier roles include leading Bergen Aquarium, Fishguard AS, and senior positions at MSD Animal Health.

"There is tremendous potential at Biomega, and what excites me about leading this company is the opportunity to drive its next phase of growth while continuing to innovate premium, sustainable products for our customers and partners," Melingen stated, adding, "I look forward to working with Biomega’s talented team to build on the strong foundation and take the company to new heights.”